NewsBenzinga强生与眼科药物开发商 Ollin Biosciences 达成 22 亿美元交易 强生与眼科药物开发商 Ollin Biosciences 达成 22 亿美元交易 Benzinga 2026.11.16 17:56 (GMT+0) Open on Benzinga Other news Ark Invest Makes Big Crypto-Related Buys Yesterday While Selling $84.8M in Nvidia Stock Abraxas Capital Closes Most of Its Hyperliquid Shorts, Account Value Down to Just $22.4 Million Nvidia Falls 35% From Record High, Short Sellers Sit on $24 Billion in Paper Profits Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory Evernorth Has Written Down Its Pre-Listing XRP Holdings by 60%
Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips
Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory